Fady Ibraham Malik Sells 2,000 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) Stock

Cytokinetics, Incorporated (NASDAQ:CYTK) EVP Fady Ibraham Malik sold 2,000 shares of the firm’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $45.98, for a total value of $91,960.00. Following the completion of the sale, the executive vice president now directly owns 116,071 shares in the company, valued at $5,336,944.58. This trade represents a 1.69 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Fady Ibraham Malik also recently made the following trade(s):

• On Tuesday, February 4th, Fady Ibraham Malik sold 2,000 shares of Cytokinetics stock. The shares were sold at an average price of $48.06, for a total value of $96,120.00.
• On Tuesday, January 21st, Fady Ibraham Malik sold 2,000 shares of Cytokinetics stock. The stock was sold at an average price of $45.92, for a total value of $91,840.00.
• On Tuesday, January 7th, Fady Ibraham Malik sold 2,000 shares of Cytokinetics stock. The stock was sold at an average price of $49.32, for a total value of $98,640.00.
• On Tuesday, December 10th, Fady Ibraham Malik sold 7,300 shares of Cytokinetics stock. The stock was sold at an average price of $50.64, for a total value of $369,672.00.
• On Tuesday, November 26th, Fady Ibraham Malik sold 7,300 shares of Cytokinetics stock. The stock was sold at an average price of $50.16, for a total value of $366,168.00.

Cytokinetics Price Performance

CYTK traded down $0.77 during trading on Tuesday, hitting $45.39. The company’s stock had a trading volume of 1,779,226 shares, compared to its average volume of 1,545,891. The firm’s 50 day moving average price is $47.43 and its two-hundred day moving average price is $51.68. The company has a quick ratio of 9.28, a current ratio of 9.28 and a debt-to-equity ratio of 5.93. Cytokinetics, Incorporated has a 12 month low of $40.53 and a 12 month high of $81.36. The stock has a market capitalization of $5.36 billion, a price-to-earnings ratio of -8.44 and a beta of 0.83.

Analyst Ratings Changes

A number of analysts have commented on the company. Needham & Company LLC reiterated a “buy” rating and issued a $72.00 price objective on shares of Cytokinetics in a research report on Thursday, February 6th. Citigroup started coverage on Cytokinetics in a research report on Friday, February 7th. They issued a “buy” rating and a $86.00 price objective for the company. JMP Securities restated a “market outperform” rating and set a $78.00 target price on shares of Cytokinetics in a research report on Friday, February 7th. Mizuho raised their target price on Cytokinetics from $99.00 to $103.00 and gave the stock an “outperform” rating in a research report on Thursday, November 21st. Finally, HC Wainwright restated a “buy” rating and set a $120.00 target price on shares of Cytokinetics in a research report on Tuesday, January 21st. Two investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $82.00.

Hedge Funds Weigh In On Cytokinetics

Institutional investors have recently bought and sold shares of the business. Jones Financial Companies Lllp raised its position in Cytokinetics by 189.8% in the 4th quarter. Jones Financial Companies Lllp now owns 571 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 374 shares during the last quarter. Centricity Wealth Management LLC acquired a new stake in shares of Cytokinetics in the 4th quarter valued at $29,000. Blue Trust Inc. increased its stake in shares of Cytokinetics by 225.9% in the 3rd quarter. Blue Trust Inc. now owns 981 shares of the biopharmaceutical company’s stock valued at $53,000 after buying an additional 680 shares during the period. Values First Advisors Inc. acquired a new stake in shares of Cytokinetics in the 3rd quarter valued at $54,000. Finally, AlphaQuest LLC increased its stake in shares of Cytokinetics by 113,500.0% in the 4th quarter. AlphaQuest LLC now owns 1,136 shares of the biopharmaceutical company’s stock valued at $53,000 after buying an additional 1,135 shares during the period.

Cytokinetics Company Profile

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.